Abstract:Background & Aims Largazole is a novel histone deacetylase (HDAC) inhibitor. This study investigated the effects of largazole against liver fibrosis. Methods The in vitro effects of largazole were examined using hepatic stellate cells (HSCs). In vivo effects of largazole were studied using a mouse liver fibrotic model induced by CCl4. Results Largazole augmented acetylation of histone H3 (H3) and histone H4 (H4) in HSCs. It directly inhibited the activation of HSCs owing to HDAC inhibitory activity as the antifibrotic effect of largazole was significantly decreased in cells with HDAC1, HDAC2 and HDAC3 knockdown. Largazole also induced apoptosis of HSCs. Largazole not only inhibited the expression of TGFR2, but also reduced phosphorylation of Smad2 and Akt induced by TGF-1. Largazole also inhibited the expression of vascular endothelial growth factor (VEGF) and its receptor. VEGF-induced proliferation of HSCs and activation of Akt and p38MAPK were also suppressed by largazole. In vivo, largazole reduced the expression of collagen I, -smooth muscle actin and tissue inhibitor of metalloproteinase-1 in CCl4induced fibrosis, and these antifibrotic effects were associated with increased acetylation of H3 and H4. Largazole also induced HSCs to undergo apoptosis in vivo, which was correlated with downregulation of bcl-2 and bcl-xL. Furthermore, largazole inhibited angiogenesis in vivo as evidenced by reduced expression of CD34, VEGF and VEGFR. In addition to its antifibrotic activity, the drug reduced inflammatory activity in CCl4-induced liver fibrosis. Conclusions Our findings revealed a novel role of largazole in the treatment of liver fibrosis. Through multiple mechanisms, largazole could be a potentially effective antifibrotic agent.

Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.

Synthetic Routes And Biological Evaluation Of Largazole And Its Analogues As Potent Histone Deacetylase Inhibitors

Synthesis and biological evaluation of largazole zinc-binding group analogs

Total Synthesis of Largazole - Devolution of A Novel Synthetic Strategy

Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.

Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry

Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships

Total Synthesis of Largazole

Discovery of a Pair of Diastereomers As Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study.

Concise Total Synthesis of Largazole

Design, Synthesis, and Biological Evaluation of Histone Deacetylase Inhibitors Derived from Erianin and Its Derivatives.

Synthesis and Biological Studies of a Triazole Analogue of Resorcylic Acid Lactone LL-Z1640-2

Total Syntheses of Epothilones A and B Via A Macrolactonization-Based Strategy

A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.

Diastereo- and Enantioselective Synthesis of β-Hydroxy-α-Amino Acids: Application to the Synthesis of a Key Intermediate for Lactacystin.

Synthesis and Structure‐activity Relationship of Thiol‐based Histone Deacetylase 6 Inhibitors

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Diastereoselective synthesis and bioactivity of long-chain anti-2-amino-3-alkanols.

A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study.

A New Synthetic Method Of Natural Product Trichostatin A

Novel N-hydroxybenzamide-based HDAC Inhibitors with Branched CAP Group.